Identification of early fibrosis stages S1 and S2 in patients with chronic hepatitis B based on T1 mapping for ECV

Motivation: Early intervention in liver fibrosis may potentially reverse and restore liver architecture and function Goal(s): Investigating the viability of utilizing 3-dimensional T1 mapping to differentiate between the liver fibrosis stage 1 (S1) and stage 2 (S2) groups. Approach: Forty-two patients with CHB complicated with liver fibrosis stage (S1-S2) were included in the study. To calculate the liver ECV, differences in the ECV values between the groups were tested using non-parametric testing. Results: The ECV values showed a statistically significant difference between the S1 and S2 stages. The AUC demonstrates good diagnostic value in distinguishing between S1 and S2. Impact: Liver ECV quantification through HCT and T1 mapping provides a relatively stable indicator for distinguishing early liver fibrosis stages S1 and S2. This non-invasive method offers clinical benefits for patients with chronic liver disease. Therefore, utilizing HCT and T1 mapping for liver ECV assessment can effectively evaluate the degree of liver fibrosis and facilitate the customization of treatment plans for patients.